BackgroundDexmedetomidine, an α2‐adrenergic agonist, reduces propofol and remifentanil requirements when used as an adjunct to total intravenous anesthesia in adults, but studies in a pediatric population are sparse. This study investigates the magnitude of dose‐sparing effects of a postinduction dexmedetomidine bolus on propofol and remifentanil requirements during pediatric surgery.MethodsIn this randomized, double‐blind, controlled trial, children aged 2–10 years undergoing elective dental surgery were assigned to one of four groups: placebo, 0.25 mcg/kg dexmedetomidine, 0.5 mcg/kg dexmedetomidine, and 1 mcg/kg dexmedetomidine. Maintenance with fixed‐ratio propofol and remifentanil total intravenous anesthesia followed a bispectral index (BIS)‐guided algorithm designed to maintain a stable depth of anesthesia. The primary outcomes were time‐averaged maintenance infusion rates of propofol and remifentanil. Secondary outcomes in the postanesthetic care unit included sedation scores, pain scores, and time to discharge.ResultsData from 67 patients were available for analysis. The median [interquartile range] propofol infusion rate was lower in the 1 mcg/kg dexmedetomidine group (180 [164–185] mcg/kg/min) versus placebo (200 [178–220] mcg/kg/min): percent change −10.0%; 95% CI −2.4 to −19.8; p = 0.013. The remifentanil infusion rate was also lower in the 1 mcg/kg dexmedetomidine group (0.089 [0.080, 0.095] mcg/kg/min) versus placebo (0.103 [0.095, 0.106] mcg/kg/min): percent change, −13.7%; 95% CI −5.47 to −21.0; p = .022. However, neither propofol nor remifentanil infusion rates were significantly different in the 0.25 or 0.5 mcg/kg dexmedetomidine groups. In the postanesthesia care unit, there were no differences in pain or sedation scores, and time to discharge was not significantly prolonged in any dexmedetomidine group.ConclusionDexmedetomidine 1 mcg/kg reduced the propofol and remifentanil requirements during maintenance of anesthesia in children when administered as a postinduction bolus.Trials RegistrationClinicalTrials.gov: NCT03422978, date of registration 2018‐02‐06.